Chas­ing the KRAS field, Quan­ta Ther­a­peu­tics bags $50M for two 2024 clin­i­cal tri­als

Quan­ta Ther­a­peu­tics will bring its KRAS in­hibitors in­to the clin­ic next year with a fresh heap of $50.7 mil­lion from blue-chip in­vestors as it looks to catch up to the KRAS lead­ers and take the dif­fi­cult class in­to oth­er mu­ta­tions and broad­er ar­eas of on­col­o­gy.

While two KRAS in­hibitors are on the mar­ket, Am­gen’s Lumakras and Mi­rati’s Kraza­ti, re­searchers and drug­mak­ers still see plen­ty of room for next-gen­er­a­tion drugs with few­er liv­er tox­i­c­i­ties, ex­pan­sion in­to oth­er mu­ta­tions and avoid­ance of re­sis­tance to the in­hibitors.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN